MSD Initiates Phase 2 Trial of Zilovertamab Vedotin vs. Polatuzumab Vedotin in GCB DLBCL
New Opportunity and Clinical Launch for ROR1 ADC
MSD (Merck Sharp & Dohme) has initiated a Phase 2 trial (waveLINE-011, NCT06890884) in April 2025 for zilovertamab vedotin (MK-2140) in combination with R-CHP in 594 newly diagnosed germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL) patients. The trial is designed as a head-to-head comparison against the standard-of-care therapy based on Roche's polatuzumab vedotin. MSD's decision to directly compare zilovertamab vedotin with a strong competitor in Phase 2 reflects strong confidence in the efficacy of its ROR1-targeting antibody-drug conjugate (ADC) candidate.
Target Differentiation and Biological Mechanism Advantages
Zilovertamab vedotin is the first ADC candidate targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). It delivers the microtubule inhibitor monomethyl auristatin E (MMAE) as a payload to selectively attack tumor cells. Interestingly, the comparator, polatuzumab vedotin, also uses MMAE as its payload but targets CD79b. Therefore, this trial will serve as a key milestone in demonstrating the efficacy differences between ADCs targeting distinct antigens (ROR1 vs. CD79b).
DLBCL Market Size and Clinical Significance
Diffuse large B-cell lymphoma (DLBCL) is the most aggressive form of non-Hodgkin lymphoma, accounting for approximately 40% of cases. Among these, the GCB subtype has a poor prognosis when treatment resistance develops, making new therapeutic options essential. The global DLBCL treatment market is projected to grow from approximately $5 billion in 2025 to around $9.9 billion by 2033. If zilovertamab vedotin demonstrates superiority in this trial, it could potentially replace polatuzumab vedotin, approved in April 2023, as the new standard of care.
VelosBio Acquisition and Financial Momentum
This trial also evaluates the value of a key asset acquired by MSD when it purchased VelosBio in November 2020 for $2.75 billion. MSD has been focusing on developing new ADC pipelines to diversify its heavy reliance on blockbuster Keytruda. The success of zilovertamab vedotin will be a critical factor in determining the commercial value of MSD's large-scale M&A strategy and its ROR1 platform. The primary endpoint evaluation is expected to be completed by December 2027, positioning it as a mid-to-long-term investment momentum.
MSD secured its ROR1-targeting ADC platform through a preemptive $2.75 billion acquisition in 2020 and is now entering a pivotal asset validation phase with this Phase 2 trial. The trial strategically employs a head-to-head comparison against Roche's polatuzumab vedotin, a standard-of-care therapy approved in April 2023, to demonstrate early efficacy superiority. If successful, the trial could position MSD to capture a rapidly growing global DLBCL first-line treatment market, projected to expand from approximately $5 billion in 2025 to $9.9 billion by 2033. From an academic standpoint, the trial is also expected to generate key data on the biological differences between two ADCs using the same MMAE payload but targeting distinct cancer antigens (ROR1 vs. CD79b).
Source: ClinicalTrials.gov (api_ct)